Abiraterone

BreastfeedingPediatric
  • TRADE NAME: Zytiga (Janssen Biotech)
  • INDICATIONS: Metastatic castration-resistant prostate cancer (in combination with prednisone)
  • CLASS: CYP17 inhibitor, Enzyme inhibitor
  • HALF-LIFE: 12 hours

FDA APPROVAL DATE: 04/28/2011

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Carbamazepine, Clarithromycin, CYP3A4 inducers or inhibitors, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, Telithromycin, Thioridazine, Voriconazole

PREGNANCY CATEGORY: X

Contra-indicated in women who are or may become pregnant.

Our database has 69 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of abiraterone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 10/29/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top